Literature DB >> 32408351

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.

Guillemette E Benoist1, Inge M van Oort2, Emmy Boerrigter1, Gerald W Verhaegh2, Onno van Hooij2, Levi Groen2, Frank Smit3, Pieter de Mol4, Paul Hamberg5, Vincent O Dezentjé6, Niven Mehra7, Winald Gerritsen7, Diederik M Somford8, Nielka P H van Erp1, Jack A Schalken2.   

Abstract

BACKGROUND: Several treatment options were recently added for metastatic castration-resistant prostate cancer (mCRPC). However, response to therapy is variable, and biomarkers that can guide treatment selection and response evaluation are lacking. Circulating RNAs are a promising source of biomarkers. We explored messenger RNAs (mRNAs), microRNAs (miRNAs), and long noncoding RNAs (lncRNAs) as potential biomarkers in liquid biopsies of patients with mCRPC treated with enzalutamide.
METHODS: Forty patients were included in this prospective multicenter observational study. Whole blood was drawn at baseline and 1, 3, and 6 months after start of therapy. Four mRNAs, 6 miRNAs, and 5 lncRNAs were analyzed by quantitative PCR. RNA levels in 30 healthy individuals were used as controls. RNA expression data were analyzed by Kaplan-Meier and Cox regression analyses, and the primary end point was progression-free survival. Clinical factors were included in the multivariable Cox regression analysis.
RESULTS: Levels of 2 miRNAs, miR-375 and miR-3687, and 1 lncRNA, N-acetylated alpha-linked acidic dipeptidase like 2 antisense RNA 2 (NAALADL2-AS2), were more than 2-fold higher in patients with mCRPC compared with healthy volunteers. Patients with higher levels of miR-375 or miR-3687 showed a shorter time to progression. Patients with higher levels of NAALADL2-AS2 showed a longer time to progression. In the multivariable Cox regression analysis, higher miR-375, miR-3687 and serum prostate-specific antigen concentrations were shown to be independent predictors for shorter time to progression.
CONCLUSIONS: We identified miR-3687 as a novel prognostic marker for response in patients with CRPC treated with enzalutamide, and we confirmed the prognostic value of miR-375. © American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Castration-resistant prostate cancer; biomarkers; enzalutamide; liquid biopsy; long noncoding RNAs; miRNAs

Mesh：

Substances：

Year:  2020        PMID： 32408351     DOI： 10.1093/clinchem/hvaa095

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  10 in total

Review 1.  The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.

Authors:  Monyse de Nóbrega; Mariana Bisarro Dos Reis; Érica Romão Pereira; Marilesia Ferreira de Souza; Ilce Mara de Syllos Cólus
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-04       Impact factor: 4.322

2.  Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.

Authors:  Marketa Koleckova; Jiri Ehrmann; Jan Bouchal; Maria Janikova; Aneta Brisudova; Josef Srovnal; Katerina Staffova; Marek Svoboda; Ondrej Slaby; Lenka Radova; Katherine Vomackova; Bohuslav Melichar; Lucia Veverkova; Zdenek Kolar
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

3.  Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1.

Authors:  Shuangshuang Mao; Sufei Zheng; Zhiliang Lu; Xinfeng Wang; Yan Wang; Guochao Zhang; Haiyan Xu; Jianbing Huang; Yuanyuan Lei; Chengming Liu; Nan Sun; Jie He
Journal:  Transl Lung Cancer Res       Date:  2021-07

4.  MicroRNAs as Potential Liquid Biopsy Biomarker for Patients with Castration-Resistant Prostate Cancer.

Authors:  Nicolas Fernandez; Julian Chavarriaga; Paola Ayala; Adriana Pedraza; John Bolivar; Juan Guillermo Prada; Juan Guillermo Cataño; Herney Andres García-Perdomo; Juliana Villanueva; Daniela Varela; Ignacio Zarante
Journal:  Res Rep Urol       Date:  2022-03-01

Review 5.  The Potential Diagnostic and Prognostic Value of Circulating MicroRNAs in the Assessment of Patients With Prostate Cancer: Rational and Progress.

Authors:  Elham Samami; Ghazaleh Pourali; Mahla Arabpour; Azar Fanipakdel; Soodabeh Shahidsales; Seyed Alireza Javadinia; Seyed Mahdi Hassanian; Saeid Mohammadparast; Amir Avan
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

Review 6.  miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer.

Authors:  Noemi Arrighetti; Giovanni Luca Beretta
Journal:  Pharmaceutics       Date:  2021-03-13       Impact factor: 6.321

Review 7.  Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.

Authors:  Eva Slabáková; Zuzana Kahounová; Jiřina Procházková; Karel Souček
Journal:  Noncoding RNA       Date:  2021-12-02

8.  Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.

Authors:  C G H Rönnau; S Fussek; F P Smit; T W Aalders; O van Hooij; P M C Pinto; M Burchardt; J A Schalken; G W Verhaegh
Journal:  World J Urol       Date:  2021-05-14       Impact factor: 4.226

9.  RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Emmy Boerrigter; Guillemette E Benoist; Inge M van Oort; Gerald W Verhaegh; Anton F J de Haan; Onno van Hooij; Levi Groen; Frank Smit; Irma M Oving; Pieter de Mol; Tineke J Smilde; Diederik M Somford; Paul Hamberg; Vincent O Dezentjé; Niven Mehra; Nielka P van Erp; Jack A Schalken
Journal:  Cancers (Basel)       Date:  2021-12-14       Impact factor: 6.639

10.  Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.

Authors:  Emmy Boerrigter; Guillemette E Benoist; Inge M van Oort; Gerald W Verhaegh; Onno van Hooij; Levi Groen; Frank Smit; Irma M Oving; Pieter de Mol; Tineke J Smilde; Diederik M Somford; Niven Mehra; Jack A Schalken; Nielka P van Erp
Journal:  Mol Oncol       Date:  2021-05-29       Impact factor: 6.603
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.